IcoSema Shows Efficacy in Type 2 Diabetes Trial
A 40-week study reveals IcoSema significantly improves glucose control and weight outcomes compared to insulin glargine.
Updated on Oct. 20, 2026 in Diabetes
Live Poll
Would you prefer a weekly diabetes injection over daily insulin if it effectively managed your blood sugar?
The COMBINE 4 phase 3b trial, published on August 13, 2026, found that once-weekly IcoSema outperforms daily insulin glargine U100 in managing blood sugar. The randomized study tracked 485 insulin-naive adults across nine countries to compare efficacy and safety.
Why it matters
This trial evaluates whether a once-weekly treatment can provide a more effective and convenient alternative for adults with type 2 diabetes who require insulin therapy. The results offer new clinical insights into managing glycemic control while addressing weight gain, a common side effect of traditional insulin regimens.
In the 485-patient study, IcoSema patients achieved a 79.8% time in target glucose range, compared to 64.5% for those on glargine U100. Gastrointestinal disorders were reported in 56% of the IcoSema group versus 21% of the glargine U100 group.
The players
COMBINE 4
This is the clinical research trial that evaluated the comparative safety and efficacy of IcoSema and insulin glargine U100 in patients with type 2 diabetes.
The details
The open-label, treat-to-target study required participants to titrate doses to achieve a fasting pre-breakfast blood glucose level of 70 to 90 mg/dL. While IcoSema recipients showed significant weight loss of 0.79 kg, those on glargine U100 experienced an average weight gain of 3.81 kg.
Timeline
February to August 2024: Patient screening period.
August 13, 2026: Trial results published online.
The Big Picture
The COMBINE 4 trial serves as a critical milestone in the ongoing development of once-weekly diabetes therapies designed to improve patient adherence. It updates the efficacy figures previously established by standard basal insulin treatments, suggesting a shift toward more flexible dosing protocols.
Patients may find that once-weekly IcoSema offers improved blood glucose management and weight control compared to daily insulin injections. However, the higher incidence of gastrointestinal side effects observed in the trial is a factor for individuals to discuss with their healthcare provider.
The takeaway
The study suggests that once-weekly therapies could eventually replace some daily insulin routines by offering better glucose stability. Patients considering new treatments should weigh these potential benefits against the risk of side effects like gastrointestinal discomfort.
Further reading
For more information on current treatment options and research, visit the Diabetes section.
More information
View the ClinicalTrials.gov trial registration details for comprehensive study parameters.
Live Poll
Would you prefer a weekly diabetes injection over daily insulin if it effectively managed your blood sugar?
